Bell KJ, Del Mar C, Wright G, . Prevalence of incidental prostate cancer: a systematic review of autopsy studies. Int J Cancer 2015;137:1749–1757.
Roach M III, Thomas K. Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States Preventive Task Force report on screening? J Natl Cancer Inst Monogr 2012;2012:221–229.
- Search Google Scholar
- Export Citation
)| false . , Roach M III Thomas K Overview of randomized controlled treatment trials for clinically localized prostate cancer: implications for active surveillance and the United States Preventive Task Force report on screening? 2012; 2012: 221– 229. 10.1093/jncimonographs/lgs039
Schröder FH, Hugosson J, Roobol MJ, . Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027–2035.
- Search Google Scholar
- Export Citation
)| false . , Schröder FH , Hugosson J , Roobol MJ Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. 2014; 384: 2027– 2035. 25108889 10.1016/S0140-6736(14)60525-0
van Leeuwen PJ, Kranse R, Hakulinen T, . Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial. J Med Screen 2013;20:33–38.
Andriole GL, Crawford ED, Grubb RL, . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009;360:1310–1319.
Pinsky PF, Prorok PC, Yu K, . Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer 2017;123:592–599.
Martin RM, Donovan JL, Turner EL, . Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial. JAMA 2018;319:883–895.
Stanford JL, Feng Z, Hamilton AS, . Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the Prostate Cancer Outcomes Study. JAMA 2000;283:354–360.
Wilt TJ, MacDonald R, Rutks I, . Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435–448.
Wilt TJ, Brawer MK, Jones KM, . Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–213.
Moyer VA; U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012;157:120–134.
Lin K, Lipsitz R, Miller T, . Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med 2008;149:192–199.
Bill-Axelson A, Holmberg L, Garmo H, . Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014;370:932–942.
Brooks JD. Managing localized prostate cancer in the era of prostate-specific antigen screening. Cancer 2013;119:3906–3909.
Barbosa PV, Thomas IC, Srinivas S, . Overall survival in patients with localized prostate cancer in the US Veterans Health Administration: is PIVOT generalizable? Eur Urol 2016;70:227–230.
Weiner AB, Patel SG, Etzioni R, . National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol 2015;193:95–102.
Grossman DC, Curry SJ, Owens DK, . Screening for prostate cancer: US Preventive Services Task Force recommendation statement. JAMA 2018;319:1901–1913.
Borza T, Kaufman SR, Shahinian VB, . Sharp decline in prostate cancer treatment among men in the general population, but not among diagnosed men. Health Aff (Millwood) 2017;36:108–115.
Jemal A, Fedewa SA, Ma J, . Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations. JAMA 2015;314:2054–2061.
Negoita S, Feuer EJ, Mariotto A, . Annual report to the nation on the status of cancer, part II: recent changes in prostate cancer trends and disease characteristics. Cancer 2018;124:2801–2814.
Hutchinson R, Akhtar A, Haridas J, . Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening. Cancer 2016;122:3785–3793.
Dimick JB, Ryan AM. Methods for evaluating changes in health care policy: the difference-in-differences approach. JAMA 2014;312:2401–2402.
Ryan AM, Burgess JF Jr, Dimick JB. Why we should not be indifferent to specification choices for difference-in-differences. Health Serv Res 2015;50:1211–1235.
Seneviratne MG, Seto T, Blayney DW, . Architecture and implementation of a clinical research data warehouse for prostate cancer. EGEMS (Wash DC) 2018;6:13.
Wallace PJ, Shah ND, Dennen T, . Optum Laboratories: building a novel node in the learning health care system. Health Aff (Millwood) 2014;33:1187–1194.
Fleshner K, Carlsson SV, Roobol MJ. The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA. Nat Rev Urol 2017;14:26–37.
Drazer MW, Huo D, Eggener SE. National prostate cancer screening rates after the 2012 US Preventive Services Task Force recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015;33:2416–2423.
Sammon JD, Abdollah F, Choueiri TK, . Prostate-specific antigen screening after 2012 US Preventive Services Task Force recommendations. JAMA 2015;314:2077–2079.
Kim SP, Karnes RJ, Gross CP, . Contemporary national trends of prostate cancer screening among privately insured men in the United States. Urology 2016;97:111–117.
Gandaglia G, Briganti A, Fossati N, . The problem is not what to do with indolent and harmless prostate cancer—the problem is how to avoid finding these cancers. Eur Urol 2016;70:547–548.
Polascik TJ, Passoni NM, Villers A, . Modernizing the diagnostic and decision-making pathway for prostate cancer. Clin Cancer Res 2014;20:6254–6257.
Jemal A, Ma J, Siegel R, . Prostate cancer incidence rates 2 years after the US Preventive Services Task Force recommendations against screening. JAMA Oncol 2016;2:1657–1660.
Potosky AL, Legler J, Albertsen PC, . Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000;92:1582–1592.
Hamdy FC, Donovan JL, Lane JA, . 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415–1424.